4559 — Zeria Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapSuper Stock

Annual income statement for Zeria Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,757	59,533	68,383	75,725	87,311
Cost of Revenue
Gross Profit	36,961	42,148	49,489	55,501	63,960
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	48,910	53,399	59,697	65,610	75,338
Operating Profit	3,848	6,134	8,686	10,115	11,973
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,957	5,722	7,273	9,508	12,619
Provision for Income Taxes
Net Income After Taxes	3,155	3,975	6,207	7,695	9,968
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,143	3,961	6,196	7,731	9,936
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,143	3,961	6,196	7,731	9,936
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	76.7	107	163	185	246
Dividends per Share